JPS6032714A - 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 - Google Patents

鼻腔粘膜に適用するための安定化された粉末状薬学的組成物

Info

Publication number
JPS6032714A
JPS6032714A JP58139466A JP13946683A JPS6032714A JP S6032714 A JPS6032714 A JP S6032714A JP 58139466 A JP58139466 A JP 58139466A JP 13946683 A JP13946683 A JP 13946683A JP S6032714 A JPS6032714 A JP S6032714A
Authority
JP
Japan
Prior art keywords
application
lower alkyl
powder
pharmaceutical composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP58139466A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0251528B2 (enExample
Inventor
Yoshiki Suzuki
嘉樹 鈴木
Hiroshi Igura
井倉　宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Priority to JP58139466A priority Critical patent/JPS6032714A/ja
Priority to EP19850300205 priority patent/EP0187433B1/en
Publication of JPS6032714A publication Critical patent/JPS6032714A/ja
Priority to US07/153,527 priority patent/US4835142A/en
Publication of JPH0251528B2 publication Critical patent/JPH0251528B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP58139466A 1983-08-01 1983-08-01 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 Granted JPS6032714A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP58139466A JPS6032714A (ja) 1983-08-01 1983-08-01 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
EP19850300205 EP0187433B1 (en) 1983-08-01 1985-01-11 Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
US07/153,527 US4835142A (en) 1983-08-01 1988-02-04 Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58139466A JPS6032714A (ja) 1983-08-01 1983-08-01 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物

Publications (2)

Publication Number Publication Date
JPS6032714A true JPS6032714A (ja) 1985-02-19
JPH0251528B2 JPH0251528B2 (enExample) 1990-11-07

Family

ID=15245886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58139466A Granted JPS6032714A (ja) 1983-08-01 1983-08-01 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物

Country Status (2)

Country Link
US (1) US4835142A (enExample)
JP (1) JPS6032714A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522997A (ja) * 2004-12-09 2008-07-03 バイエル・ヘルスケア・アクチェンゲゼルシャフト 酸によるグルココルチコイドエステルの安定化

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
US5248310A (en) * 1992-03-27 1993-09-28 Alza Corporation Oral osmotic device with hydrogel driving member
US5512299A (en) * 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
JPH07140076A (ja) * 1993-11-12 1995-06-02 Bio Sensor Kenkyusho:Kk 粉体酸化剤組成物
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
CN1155368C (zh) * 1996-02-27 2004-06-30 帝人株式会社 鼻腔给药的粉剂组合物
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US20010053775A1 (en) * 1998-01-30 2001-12-20 Matthias Seidel Nasal solutions
JPH11246439A (ja) * 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
CN1160079C (zh) 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
WO2000023023A1 (en) 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
WO2000074736A1 (en) 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
BR0108730A (pt) * 2000-02-28 2002-11-05 Vectura Ltd Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
US6881731B1 (en) * 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
HU229344B1 (en) * 2001-02-27 2013-11-28 Evonik Roehm Gmbh Coating and binding agent for pharmaceutical formulations with improved storage stability
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
SI1663235T1 (sl) 2003-08-18 2013-12-31 Parion Sciences, Inc. Zaščiteni pirazinoilgvanidinski blokatorji natrijevega kanala
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
EP1668035A2 (en) * 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
CN103223160B (zh) * 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
UA88663C2 (en) * 2004-12-09 2009-11-10 Баер Энимал Хелс Гмбх Stabilisation of glucocorticoid esters with acids
RU2437679C2 (ru) * 2004-12-09 2011-12-27 Байер Энимэл Хельс ГмбХ Стабилизация сложных эфиров глюкокортикоидов кислотами
DK200500028A (da) * 2005-01-07 2006-08-11 Hansen Richard Brinch Preparation for preventing or treating calcium deficiency conditions in mammals
EP1909834A2 (en) * 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
CA2631212A1 (en) * 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
US9241908B2 (en) * 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
AU2009246799B2 (en) 2008-02-26 2014-02-27 Parion Sciences, Inc. Poly aromatic pyrazinoylguanidine sodium channel blockers
PL2723176T3 (pl) 2011-06-27 2018-01-31 Parion Sciences Inc Chemicznie i metabolicznie stabilny dipeptyd o silnej aktywności blokera kanału sodowego
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
PE20151054A1 (es) 2012-12-17 2015-08-07 Parion Sciences Inc Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3276959A (en) * 1963-08-08 1966-10-04 Hefa G M B H Stabilized steroid compositions
JPS54158435A (en) * 1978-06-05 1979-12-14 Nippon Shikizai Kogyo Kenkyusho:Kk Surface treatment
US4294952A (en) * 1978-11-30 1981-10-13 Hitachi Chemical Company, Ltd. Polyamide-imide resin and its production
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
US4289764A (en) * 1979-12-04 1981-09-15 Drythanol Ltd. Steroid compositions
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522997A (ja) * 2004-12-09 2008-07-03 バイエル・ヘルスケア・アクチェンゲゼルシャフト 酸によるグルココルチコイドエステルの安定化

Also Published As

Publication number Publication date
US4835142A (en) 1989-05-30
JPH0251528B2 (enExample) 1990-11-07

Similar Documents

Publication Publication Date Title
JPH0251528B2 (enExample)
CA2372231C (en) Aerosol formulations and devices for increasing libido in women via acute testosterone administration
AU2006256518B2 (en) Method and composition for treating inflammatory disorders
BR9710115B1 (pt) composiÇço aquosa farmacÊutica, e processo de preparaÇço de uma composiÇço aquosa farmacÊutica.
KR101052693B1 (ko) 건조 분말 흡입용 조성물의 제조방법
JPS6034925B2 (ja) 持続性鼻腔用製剤およびその製造法
JP3221880B2 (ja) 抗うつ作用を有する医薬組成物としての２‐アミノ‐６‐ｎ‐プロピル‐アミノ‐４，５，６，７‐テトラヒドロベンゾチアゾールの使用
BG65350B1 (bg) Стабилен концентрат на формотерол
TW200524615A (en) Aqueous suspensions of ciclesonide for nebulisation
EP0187433A1 (en) Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
EP1137398B1 (en) Pharmaceutical preparation for inhalation of an opioid
JP2021506897A (ja) フドステインのエアロゾル吸入用溶液製剤及びその製造方法
EA035740B1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
AU2004285592B2 (en) Soft steroid compositions for use in dry powder inhalers
JP2005132801A (ja) 口腔内崩壊錠
ITMI20010428A1 (it) Composizioni ad uso inalatorio a base di formoterolo
AU2007311607A1 (en) Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
JP3386348B2 (ja) 鼻腔内投与用水性懸濁製剤
CN112137957B (zh) 一种药用吸入气雾剂及其制备方法
WO2003068315A1 (en) A pulmonary drug delivery composition containing a progestogen and an androgen for use in a contraceptive method in males
JP5171102B2 (ja) 経鼻吸収用睡眠導入剤
KR870001374B1 (ko) 구강 또는 비강점막용 분말상 제약적 조성물의 제조방법
JP2005281315A6 (ja) 水性薬理組成物
JP2005281315A (ja) 水性薬理組成物
JP2004018491A (ja) プロスタグランジン含有経鼻投与製剤組成物